Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Treating Moderate-to-Severe Plaque Psoriasis in Patients 50+ Including the Medicare Population

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in for a discussion about an IL-23 inhibitor that helps optimize the management of patients 50+ with moderate-to-severe plaque psoriasis. 

  • Sponsored by

  • Overview

    Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.

  • INDICATION

    ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  • IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

    WARNINGS AND PRECAUTIONS 
    Hypersensitivity
    Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

    Infections
    ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

    Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.

    Pretreatment Evaluation for Tuberculosis
    Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.

    Immunizations
    Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

    Adverse Reactions
    The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

    ILUMYA trademarks and related logos are owned or licensed to Sun Pharma group companies. All other trademarks are the property of their respective owners.

Schedule9 Dec 2024